Cargando…
Second breast conserving therapy after ipsilateral breast tumor recurrence – a 10-year experience of re-irradiation
PURPOSE: The aim of this study is to evaluate the efficacy and toxicity of post-operative partial breast re-irradiation with multi-catheter brachytherapy after second breast conserving therapy (BCT) in patients with small, low-risk ipsilateral breast tumor recurrence (IBTR). MATERIAL AND METHODS: Be...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6737570/ https://www.ncbi.nlm.nih.gov/pubmed/31523231 http://dx.doi.org/10.5114/jcb.2019.87001 |
_version_ | 1783450678472998912 |
---|---|
author | Forster, Tobias Akbaba, Sati Schmitt, Daniela Krug, David El Shafie, Rami Oelmann-Avendano, Jan Lindel, Katja König, Laila Arians, Nathalie Bernhardt, Denise Marmé, Frederik Schneeweiss, Andreas Heil, Jörg Sohn, Christof Debus, Jürgen Hörner-Rieber, Juliane |
author_facet | Forster, Tobias Akbaba, Sati Schmitt, Daniela Krug, David El Shafie, Rami Oelmann-Avendano, Jan Lindel, Katja König, Laila Arians, Nathalie Bernhardt, Denise Marmé, Frederik Schneeweiss, Andreas Heil, Jörg Sohn, Christof Debus, Jürgen Hörner-Rieber, Juliane |
author_sort | Forster, Tobias |
collection | PubMed |
description | PURPOSE: The aim of this study is to evaluate the efficacy and toxicity of post-operative partial breast re-irradiation with multi-catheter brachytherapy after second breast conserving therapy (BCT) in patients with small, low-risk ipsilateral breast tumor recurrence (IBTR). MATERIAL AND METHODS: Between 2008 and 2018, 19 consecutive patients with low-risk IBTR (max. rpT1 cN0 cM0, Her2 negative, preferably positive hormone receptor status) who refused mastectomy were treated with salvage lumpectomy, followed by post-operative partial breast re-irradiation with multi-catheter brachytherapy. Eight patients were irradiated using PDR brachytherapy (49.8-50.4 Gy in pulses of 0.5-0.7 Gy) and 11 patients using HDR brachytherapy (34.2 Gy in fractions of 3.8 Gy or 32 Gy in fractions of 4 Gy). All patients had undergone prior BCT for their primary tumor, followed by adjuvant whole breast radiotherapy. Local control (LC), locoregional control (LRC), overall survival (OS), disease-free survival (DFS) as well as toxicity were evaluated in the present study. RESULTS: After a median follow-up of 65 months following IBTR (18-120 months), only one second IBTR in 19 patients was diagnosed 77 months after re-irradiation, resulting in a LC rate of 100% at 5 years. DFS and OS rates were both 100% at 5 years following re-irradiation. Except for the above mentioned second IBTR, no regional or distant relapse was recorded. Regarding toxicity, 63% of patients developed adverse events (CTCAE grade ≤ 2), with fibrosis detected in 37% (7/19) of patients, necrosis in 11% (2/19), hyperpigmentation in 47% (9/19), and telangiectasia in 11% (2/19), respectively. No patient showed a high-grade (CTCAE grade ≥ 3) adverse event. CONCLUSIONS: In case of small, low-risk IBTR, adjuvant re-irradiation using multi-catheter brachytherapy is a feasible, safe, and effective treatment method after repeated lumpectomy, and an alternative to mastectomy. |
format | Online Article Text |
id | pubmed-6737570 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Termedia Publishing House |
record_format | MEDLINE/PubMed |
spelling | pubmed-67375702019-09-13 Second breast conserving therapy after ipsilateral breast tumor recurrence – a 10-year experience of re-irradiation Forster, Tobias Akbaba, Sati Schmitt, Daniela Krug, David El Shafie, Rami Oelmann-Avendano, Jan Lindel, Katja König, Laila Arians, Nathalie Bernhardt, Denise Marmé, Frederik Schneeweiss, Andreas Heil, Jörg Sohn, Christof Debus, Jürgen Hörner-Rieber, Juliane J Contemp Brachytherapy Original Paper PURPOSE: The aim of this study is to evaluate the efficacy and toxicity of post-operative partial breast re-irradiation with multi-catheter brachytherapy after second breast conserving therapy (BCT) in patients with small, low-risk ipsilateral breast tumor recurrence (IBTR). MATERIAL AND METHODS: Between 2008 and 2018, 19 consecutive patients with low-risk IBTR (max. rpT1 cN0 cM0, Her2 negative, preferably positive hormone receptor status) who refused mastectomy were treated with salvage lumpectomy, followed by post-operative partial breast re-irradiation with multi-catheter brachytherapy. Eight patients were irradiated using PDR brachytherapy (49.8-50.4 Gy in pulses of 0.5-0.7 Gy) and 11 patients using HDR brachytherapy (34.2 Gy in fractions of 3.8 Gy or 32 Gy in fractions of 4 Gy). All patients had undergone prior BCT for their primary tumor, followed by adjuvant whole breast radiotherapy. Local control (LC), locoregional control (LRC), overall survival (OS), disease-free survival (DFS) as well as toxicity were evaluated in the present study. RESULTS: After a median follow-up of 65 months following IBTR (18-120 months), only one second IBTR in 19 patients was diagnosed 77 months after re-irradiation, resulting in a LC rate of 100% at 5 years. DFS and OS rates were both 100% at 5 years following re-irradiation. Except for the above mentioned second IBTR, no regional or distant relapse was recorded. Regarding toxicity, 63% of patients developed adverse events (CTCAE grade ≤ 2), with fibrosis detected in 37% (7/19) of patients, necrosis in 11% (2/19), hyperpigmentation in 47% (9/19), and telangiectasia in 11% (2/19), respectively. No patient showed a high-grade (CTCAE grade ≥ 3) adverse event. CONCLUSIONS: In case of small, low-risk IBTR, adjuvant re-irradiation using multi-catheter brachytherapy is a feasible, safe, and effective treatment method after repeated lumpectomy, and an alternative to mastectomy. Termedia Publishing House 2019-08-29 2019-08 /pmc/articles/PMC6737570/ /pubmed/31523231 http://dx.doi.org/10.5114/jcb.2019.87001 Text en Copyright: © 2019 Termedia Sp. z o. o. http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license. |
spellingShingle | Original Paper Forster, Tobias Akbaba, Sati Schmitt, Daniela Krug, David El Shafie, Rami Oelmann-Avendano, Jan Lindel, Katja König, Laila Arians, Nathalie Bernhardt, Denise Marmé, Frederik Schneeweiss, Andreas Heil, Jörg Sohn, Christof Debus, Jürgen Hörner-Rieber, Juliane Second breast conserving therapy after ipsilateral breast tumor recurrence – a 10-year experience of re-irradiation |
title | Second breast conserving therapy after ipsilateral breast tumor recurrence – a 10-year experience of re-irradiation |
title_full | Second breast conserving therapy after ipsilateral breast tumor recurrence – a 10-year experience of re-irradiation |
title_fullStr | Second breast conserving therapy after ipsilateral breast tumor recurrence – a 10-year experience of re-irradiation |
title_full_unstemmed | Second breast conserving therapy after ipsilateral breast tumor recurrence – a 10-year experience of re-irradiation |
title_short | Second breast conserving therapy after ipsilateral breast tumor recurrence – a 10-year experience of re-irradiation |
title_sort | second breast conserving therapy after ipsilateral breast tumor recurrence – a 10-year experience of re-irradiation |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6737570/ https://www.ncbi.nlm.nih.gov/pubmed/31523231 http://dx.doi.org/10.5114/jcb.2019.87001 |
work_keys_str_mv | AT forstertobias secondbreastconservingtherapyafteripsilateralbreasttumorrecurrencea10yearexperienceofreirradiation AT akbabasati secondbreastconservingtherapyafteripsilateralbreasttumorrecurrencea10yearexperienceofreirradiation AT schmittdaniela secondbreastconservingtherapyafteripsilateralbreasttumorrecurrencea10yearexperienceofreirradiation AT krugdavid secondbreastconservingtherapyafteripsilateralbreasttumorrecurrencea10yearexperienceofreirradiation AT elshafierami secondbreastconservingtherapyafteripsilateralbreasttumorrecurrencea10yearexperienceofreirradiation AT oelmannavendanojan secondbreastconservingtherapyafteripsilateralbreasttumorrecurrencea10yearexperienceofreirradiation AT lindelkatja secondbreastconservingtherapyafteripsilateralbreasttumorrecurrencea10yearexperienceofreirradiation AT koniglaila secondbreastconservingtherapyafteripsilateralbreasttumorrecurrencea10yearexperienceofreirradiation AT ariansnathalie secondbreastconservingtherapyafteripsilateralbreasttumorrecurrencea10yearexperienceofreirradiation AT bernhardtdenise secondbreastconservingtherapyafteripsilateralbreasttumorrecurrencea10yearexperienceofreirradiation AT marmefrederik secondbreastconservingtherapyafteripsilateralbreasttumorrecurrencea10yearexperienceofreirradiation AT schneeweissandreas secondbreastconservingtherapyafteripsilateralbreasttumorrecurrencea10yearexperienceofreirradiation AT heiljorg secondbreastconservingtherapyafteripsilateralbreasttumorrecurrencea10yearexperienceofreirradiation AT sohnchristof secondbreastconservingtherapyafteripsilateralbreasttumorrecurrencea10yearexperienceofreirradiation AT debusjurgen secondbreastconservingtherapyafteripsilateralbreasttumorrecurrencea10yearexperienceofreirradiation AT hornerrieberjuliane secondbreastconservingtherapyafteripsilateralbreasttumorrecurrencea10yearexperienceofreirradiation |